We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic (HOLX) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
In the latest trading session, Hologic (HOLX - Free Report) closed at $71.74, marking a -0.49% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. Elsewhere, the Dow lost 0.36%, while the tech-heavy Nasdaq lost 0.16%.
Heading into today, shares of the medical device maker had lost 6.22% over the past month, outpacing the Medical sector's loss of 6.83% and lagging the S&P 500's loss of 2.36% in that time.
Analysts and investors alike will be keeping a close eye on the performance of Hologic in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $1.01, marking a 3.06% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $1.03 billion, up 1.39% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $4.29 per share and a revenue of $4.17 billion, signifying shifts of +5.15% and +3.53%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Hologic. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.04% higher. Hologic is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that Hologic has a Forward P/E ratio of 16.82 right now. This denotes a discount relative to the industry's average Forward P/E of 26.77.
We can additionally observe that HOLX currently boasts a PEG ratio of 2.45. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Medical - Instruments stocks are, on average, holding a PEG ratio of 2 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 71, putting it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic (HOLX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Hologic (HOLX - Free Report) closed at $71.74, marking a -0.49% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. Elsewhere, the Dow lost 0.36%, while the tech-heavy Nasdaq lost 0.16%.
Heading into today, shares of the medical device maker had lost 6.22% over the past month, outpacing the Medical sector's loss of 6.83% and lagging the S&P 500's loss of 2.36% in that time.
Analysts and investors alike will be keeping a close eye on the performance of Hologic in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $1.01, marking a 3.06% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $1.03 billion, up 1.39% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $4.29 per share and a revenue of $4.17 billion, signifying shifts of +5.15% and +3.53%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Hologic. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.04% higher. Hologic is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that Hologic has a Forward P/E ratio of 16.82 right now. This denotes a discount relative to the industry's average Forward P/E of 26.77.
We can additionally observe that HOLX currently boasts a PEG ratio of 2.45. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Medical - Instruments stocks are, on average, holding a PEG ratio of 2 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 71, putting it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.